Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2006

View Archived Issues

Lorus Therapeutics: Q2 review

Phase IIb draft protocol submitted for CF-101 in rheumatoid arthritis

Enrollment open in phase Ib study of PX-12 for advanced gastrointestinal cancers

Independent confirmations of NeuGene efficacy against influenza strains

Inspire discontinues development of denufosol tetrasodium for retinal diseases

Biovitrum and Syntonix sign agreement for long-acting recombinant Factor IX

CytRx plans open-label extension to phase II ALS study of arimoclomol

Spectrum to benefit from satraplatin license agreement

Cloretazine receives European orphan drug designation for AML

Tosufloxacin tosilate ophthalmic solution approved in Japan

Dyloject relieves postoperative pain faster than ketorolac in phase IIb study

Advisory Committee sets date for Cubicin sNDA review

FDA Advisory Committee recommends OTC approval of orlistat 60 mg

Phase IIb study of obesity drug AOD-9604 proceeds on schedule

Attenuated human rotavirus vaccine effective against severe gastroenteritis

Antitumor activity of SU-11248 evaluated in phase I and II trials

Studies indicate GR-270773 can be used with levofloxacin and propofol

MP-4 safe, reduces hypotensive episodes in orthopedic surgery patients

Antisense technology protects 75% of monkeys against Ebola

Stat3 as a target for inducing antitumor immune response

Recent patents cover therapeutic agents for neurological disorders

Recent Taisho and Rib-X patents describe novel antiinfective agents

Therapeutic agents for hepatitis C infection jointly claimed by Merck and Isis

European approval for Cubicin in complicated skin and soft-tissue infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...